Novartis Typhoid Vaccine Seeks Partner After Securing Pakistan Clinical Trial Site
This article was originally published in PharmAsia News
Phase II study is ongoing in Pakistan, a year after Novartis convinced the Pakistani government to lift its ban on clinical trials. Antimalarials with a different mechanism of action than Coartem are in Phase I and II trials.
You may also be interested in...
WHO committee backs use of pooled funds to finance R&D, nixes priority review vouchers and finds no need for data exclusivity. Novartis’ Paul Herrling, a committee member, notes that governments would be responsible for R&D costs.
On New Year's Eve in 2005, the operators of Novartis' plant in Suffern, N.Y. were jubilant. The facility had just manufactured its 20 millionth treatment of Coartem (artemether/lumefantrine)
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.